Skip to main content
PLOS Computational Biology logoLink to PLOS Computational Biology
. 2021 Jul 26;17(7):e1009206. doi: 10.1371/journal.pcbi.1009206

Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations

Jessica L Kingsley 1,2, James R Costello 3, Natarajan Raghunand 4,5, Katarzyna A Rejniak 1,5,*
Editor: Philip K Maini6
PMCID: PMC8341701  PMID: 34310608

Abstract

Radiologic images provide a way to monitor tumor development and its response to therapies in a longitudinal and minimally invasive fashion. However, they operate on a macroscopic scale (average value per voxel) and are not able to capture microscopic scale (cell-level) phenomena. Nevertheless, to examine the causes of frequent fast fluctuations in tissue oxygenation, models simulating individual cells’ behavior are needed. Here, we provide a link between the average data values recorded for radiologic images and the cellular and vascular architecture of the corresponding tissues. Using hybrid agent-based modeling, we generate a set of tissue morphologies capable of reproducing oxygenation levels observed in radiologic images. We then use these in silico tissues to investigate whether oxygen fluctuations can be explained by changes in vascular oxygen supply or by modulations in cellular oxygen absorption. Our studies show that intravascular changes in oxygen supply reproduce the observed fluctuations in tissue oxygenation in all considered regions of interest. However, larger-magnitude fluctuations cannot be recreated by modifications in cellular absorption of oxygen in a biologically feasible manner. Additionally, we develop a procedure to identify plausible tissue morphologies for a given temporal series of average data from radiology images. In future applications, this approach can be used to generate a set of tissues comparable with radiology images and to simulate tumor responses to various anti-cancer treatments at the tissue-scale level.

Author summary

Low levels of oxygen, called hypoxia, are observable in many solid tumors. They are associated with more aggressive malignant cells that are resistant to chemo-, radio-, and immunotherapies. Recently developed imaging techniques provide a way to measure the magnitude of frequent short-term oxygen fluctuations, but they operate on a macro-scale voxel level. To examine the possible causes of rapid oxygen fluctuations at the cell level, we developed a hybrid agent-based mathematical model. We tested two different mechanisms that may be responsible for these cyclic effects on tissue oxygenation: temporal variations in vascular influx of oxygen and modulations in cellular oxygen absorption. Additionally, we developed a procedure to identify plausible tissue morphologies from data collected from radiological images. This can provide a bridge between the micro-scale simulations with individual cells and the longitudinal medical images containing average values. In future applications, this approach can be used to generate a set of tissues compatible with radiology images and to simulate tumor responses to various anticancer treatments at the cell-scale level.

Introduction

Tumor tissues harbor regions of different levels of oxygen, including the well-oxygenated areas (normoxia) and zones with reduced oxygen availability (hypoxia). The hypoxic regions can arise as a result of rapid proliferation of tumor cells and tortuous tumor vasculature, which together lead to an increased distance between some tumor cells and the nearest blood vessel. This, in turn, results in the emergence of oxygen gradients and a diffusion-limited hypoxia, usually at the distances of 120–180 μm from vasculature[1]. Such chronic hypoxia, with oxygen partial pressure (pO2) below 10 mmHg, may last for a prolonged periods of time, often for more than 24 hours[2,3]. However, hypoxic regions can also be created due to irregular blood flow in the aberrant tumor vasculature or shutdown of small vessels. These phenomena lead to a perfusion-limited hypoxia that is observable for shorter times, often minutes to hours, and can be reversed when the blood flow is restored[2,3]. Several studies have demonstrated the existence of 20–30 minute-long cycles in red blood cell flux that can vary by 2–5 fold and lead to periodic changes in pO2 within the tumor tissue[35]. However, it has also been observed in murine experiments that tumors experience very fast and sometimes quite large fluctuations (more than 5-fold) in oxygen levels within the tissue. In particular, electron paramagnetic resonance (EPR) imaging has shown that intratumor fluctuations in pO2 can reach a magnitude as high as 30 mmHg over a period as short as 3 minutes[6,7].

EPR imaging is a spectroscopic technique that can detect molecules presenting unpaired electrons. However, viable tissues contain insufficient amounts of radical species, so EPR requires the injection of a paramagnetic probe to enable visualization of pO2[8]. One such a probe, the triaryl-methyl (TAM) radicals, are injected intravascularly to serve as a tracer for mapping and quantifying tissue pO2 in live animals[6,7]. As a result of collisions between TAM and O2 molecules, the TAM spectral line width broadens in proportional to pO2 and can be detected by the EPR scanner. The subsequent oxygen image reconstruction provides quantitative maps of pO2 distribution within the tissue[9]. The typical EPR voxel has a resolution of 1mm3, and average pO2 values from each volumetric voxel are collected in the form of 2D oxygenation maps (compare Fig 2 in [6]). The EPR oxygenation maps show spatial variations in the xy-plane, but are not able to capture variations in the third dimension.

This imaging technique was used to record intratumoral pO2 fluctuations in the squamous cell carcinoma VII (SCCVII) of size 1,200 mm3 shown in Fig 2 of [6]. In this experiment, four regions of interest (ROIs) were selected based on an anatomical image of the tumor from the T2-weighted magnetic resonance imaging (MRI). EPR imaging was used to record pO2 maps that were co-registered with the MRI image and average values of pO2 in each ROI were recorded every 3 minutes for 24 minutes. The pO2 maps correspond to the last data set (at 28 minutes). The four chosen ROIs are characterized by different initial levels of pO2, from a very well oxygenated Region #1 to a severely hypoxic Region #4. Regions #1 and #2 showed significant changes in pO2 during the time of experiment (more than 10-fold), while Regions #3 and #4 displayed more uniform levels of pO2 during the whole experiment. Since the EPR imaging operates on the resolution of millimeters (macroscale), it is impossible to determine which biological mechanisms are responsible for such fast and relatively large (more than 5-fold) oxygen fluctuations. To address this issue, the modeling on a cellular level (microscale) is needed.

Motivated by these experimental data, we use the hybrid agent-based MultiCell-LF (multi-cell lattice-free[10,11]) model to test mechanisms that could be responsible for cyclic effects in tissue oxygenation. In general, the distribution of blood-borne compounds (oxygen, nutrients, drugs, etc.) within the tissue depends on the localization and amount of compound entering the tissue (vascular supply), the amount and localization of compound leaving the tissue (cellular uptake), and compound interstitial transport. We consider here the first two mechanisms only. Since the experiments were performed over a very short period of time (30 minutes), no significant modifications in oxygen transport were expected. Such modifications can arise only due to changes in the number or localization of cells or vessels, or if the extracellular matrix composition changes. In a half hour period and with no therapeutic interventions (such as radiotherapy or surgery), no changes in the number of cells (no proliferation, no death), in the vasculature (no angiogenesis, no vascular collapse due to tumor growth), nor in the ECM structure (no ECM production by stromal cells) are anticipated. Additionally, in the experiments described above, the levels of an EPR-specific tracer (TAM) were recorded, but no detectable changes in tracer levels or distribution were observed within each ROI (compare Fig 2 from[6]). This also suggests that the observed oxygen fluctuations are not related to changes in the interstitial transport. Therefore, we tested whether the modifications in vascular oxygen supply or in cellular oxygen absorption can contribute to the observed variations in tissue oxygenation.

The rest of the paper is organized as follows. The mathematical model is described in section 2 and used to design a collection of tumor tissues (section 3.1) with a numerically stable oxygen distribution (section 3.2). Next, for four tissues that match the average pO2 value in each experimental ROI (section 3.3), we determine optimal rates of oxygen vascular influx or oxygen cellular uptake that fit the experimentally observable fluctuations in pO2 (section 3.4). These optimal schedules are then applied to a larger sample of in silico tissues with initial pO2 values close to the experimental data to assess schedules’ robustness and reproducibility (section 3.5). Finally, we discuss implications of our findings for tumor development and future applications (section 4).

Methods–mathematical model

For this study, we consider a two-dimensional tissue patch with an area of 1 mm2 that corresponds to a cross section of a typical EPR imaging voxel and a single element in the EPR oxygen map[12,13]. Tissue morphology and metabolism is modeled using the MultiCell-LF model, which combines the off-lattice individual vessels and cells (tumor and stromal) with a continuous description of oxygen kinetics. A typical example from our simulations is shown in Fig 1. The specific oxygen distribution within the tissue depends on three factors: the amount of oxygen supplied from individual vessels, the amount of oxygen absorbed by both tumor and stromal cells, and the spatial localization of all cells and vessels. As a result of this influx-outflux balance, an irregular oxygen distribution pattern can emerge.

Fig 1. Mathematical model of the tumor tissue microenvironment.

Fig 1

A. A contour map of the simulated oxygen distribution. The color scheme corresponds to that used in EPR imaging for the partial pressure of oxygen (cyan: low pO2; white: high pO2). B. Locations of tumor vasculature (red circles), tumor cells (purple circles), and stromal cells (pink circles) within the same computational domain; this is used to define tissue cellularity and vascularity. The color scheme corresponds to typical colors in histology images. C. Magnification of a quarter of the computational domain showing all model components together: the vessels, tumor and stromal cells, and oxygen distribution. All variables are dimensional (length is in μm, oxygen partial pressure in mmHg, as listed in Table 1).

Tissue design

Initially, the locations of tumor cells, stromal cells and vessels were chosen randomly within the tissue domain. To ensure that the cells did not overlap with one another and with the vessels, repulsive forces were applied to all cells. Let Xi and Xj represent the coordinates of two discrete elements (either tumor cells, stromal cells or vessels) of radii Ri and Rj, respectively. The repulsive Hookean force fXi,Xj of stiffness F acting on element Xi is given by:

fXi,Xj={F((Ri+Rj)XiXj)XiXjXiXjifXiXj<Ri+Rj0otherwise.

For the tissue that contains NV vessels of coordinates Vi=(Vix,Viy), NT tumor cells of coordinates Tj=(Tjx,Tjy), and NS stromal cells of coordinates Sk=(Skx,Sky), the repulsive forces FjT acting on tumor cells and FkS acting on stromal cells combine contributions from all nearby tumor cells, stromal cells and vessels, and are given by the following equations:

FjT=ljNTfTj,Tl+k=1NSfTj,Sk+i=1NVfTj,Viforj=1NT
FkS=lkNTfSk,Sl+j=1NTfSk,Tj+i=1NVfSk,Vifork=1NS

To resolve the overlapping conditions, the tumor and stromal cells are relocated following the overdamped spring equation, where ν is the viscosity of the surrounding medium:

dTjdt=1νFjTanddSkdt=1νFkS.

We apply these equations iteratively to all overlapping tumor and stromal cells until the equilibrium is reached, where FjT=FkS=0 (Fig A in S1 Text). The vessels are not subject to relocation, and we allow the vessels to overlap with other vessels to represent different vascular shapes observed in tissue histologic samples that result from the angle at which the tissue slices are cut. This algorithm is only used in the initial phase to create the tissue and thus the same spring stiffness is used for all repulsive forces. Once the overlapping conditions are resolved for all cells, the repulsive forces are deactivated. The cells and vessels are immobile during the oxygen fluctuation period, and cell proliferation and death are neglected during the simulated 30-minute period.

Oxygen distribution

Oxygen distribution within the tissue γ(x,t) depends on its influx from vessels, diffusion through the tissue, and the uptake by both stromal and tumor cells. Influx is determined by the location of each individual vessel Vi and the influx rate δV(t), which can vary over time. The influx rate represents a fraction (0≤δV(t)≤1) of the maximum oxygen supply γmax characteristic of the oxygen content in the vessels of a given radius RV. The transport through the interstitial space of the tumor tissue is assumed to have a constant diffusion coefficient Dγ. The oxygen uptake is defined by the Michaelis-Menten equation with a Michaelis constant κm common for both tumor and stromal cells, the constant maximum uptake rate for stromal cells Smax, and the maximum uptake rate for tumor cells δT(t)Tmax for which the rate (δT(t)≥0) can change over time. The oxygen kinetics is modeled using the following continuous reaction-diffusion equation:

γ(x,t)t=i=1NVδV(t)γmaxχRV(x,Vi)influx+Dγγ(x,t)diffusionj=1NTδT(t)Tmaxγ(x,t)κm+γ(x,t)χRT(x,Tj)uptakebytumorcellsk=1NSSmaxγ(x,t)κm+γ(x,t)χRS(x,Sk)uptakebystromalcells

Interactions between oxygen defined on the Cartesian grid x = (x,y) and the tumor cells, stromal cells and vessels defined on the Lagrangian grid X = (X,Y) are specified by the indicator function, χR(x, X), with the interaction radius R:

χR(x,X)={1xX<R0otherwise

To generate the initial numerically stable oxygen distribution, the oxygen influx rate for each vessel was set up to the maximum vascular level (δV(t) = 1) and the tumor cellular uptake was set up to the base uptake level (δT(t) = 1). However, in order to generate oxygen fluctuations in the whole tissue, one or both of these rates were varied. The rates are based on experimentally observable changes in red blood cell flux in tumor vasculature[4] and changes in oxygen uptake by tumor cells grown in different microenvironmental conditions[14,15]. The values of all other model parameters are listed in Table 1 and more information is provided in S1 Text.

Table 1. Model physical and computational parameters.

Physical parameters Value References
Tumor cell diameter 2RT = 15 μm [16,17]
Stromal cell diameter 2RS = 7.5 μm [18]
Vessel diameter 2RV = 40 μm [19]
Force stiffness F=50μg/μms2 [20,21]
Medium viscosity ν = 250 μg/μms [22]
Oxygen diffusion Dγ=100μm2/s [23,24]
Vascular level of oxygen γmax = 60 σg/μm3[60 mmHg] [6,19,25]
Michaelis constant κm = 134 σg/μm3 [26]
Tumor base oxygen uptake rate Tmax = 0.382 σg/s * cell volume [26]
Stromal base oxygen uptake rate Smax = 0.382 σg/s * cell volume [26]
Influx rate 0≤δV(t)≤1
Uptake rate 0≤δT(t)≤50
Computational parameters
Domain size Ω = [−500,500]×[−500,500] μm2
Grid width Δx = 5 μm
Time step Δt = 0.05 s
Scaling parameter σg = 0.5×10−19g = 0.05 ag

Results

The goal of this study is to identify the possible mechanisms leading to fast (within 3-minute duration) fluctuations in oxygen level observed in in vivo tumors. To do that, we first generated a collection of tumor tissues that varied in their vascular and cellular fractions (section 3.1) and determined the numerically stable oxygen distribution within these tissues (section 3.2). Next, we identified in silico tissues for which the average pO2 values best fit the four specific experimental data (section 3.3). These tissues were used to investigate whether the observed short-term oxygen fluctuations can arise as an effect of altered oxygen supply from the vasculature or altered oxygen uptake by tumor cells (section 3.4). The identified optimal influx/uptake schedules were then applied to a larger sample of in silico tissues with initial pO2 levels close to the experimental data to assess the schedules’ robustness and reproducibility (section 3.5).

Generation of in silico tissues with a stable oxygen distribution

In general, the oxygen distribution within the tissue—that is, the extent and localization of well-oxygenated vs. hypoxic regions—depend on the number and placement of vessels and both tumor and stromal cells. Therefore, we generated a collection of in silico tissues with different vascularity (a fraction of the tissue that is occupied by the vessels), as well as tumor and stromal cellularity (a fraction of the tissue populated by tumor or stromal cells, respectively). In particular, we considered tissue vascularity to be between 0.5% and 5% of the whole tissue area, in increments of 0.5%. The fractions of tissue inhabited by tumor cells was varied between 10% and 95%, and by stromal cells between 5% and 95%, both in increments of 5%. We have ensured that the total of cellular and vascular fractions does not exceed 100% of the tissue area. The locations of all vessels and cells were chosen randomly, and we applied the repulsive force algorithm described above to resolve overlaps between the cells and vessels. In all of these simulations, the oxygen influx from vessels was assumed identical (with δV(t) = 1), as was the oxygen uptake by each tumor cell (with δT(t) = 1).

For each in silico tissue, we applied the diffusion-reaction equation of oxygen kinetics to generate a stable oxygen distribution. As a stability criterion, we calculated the L2-norm between two consecutive oxygen distributions:

εγn=γnγn12=i,j=1Ni,Nj(γijnγijn1)2

where, γijn=γ(xij,tn) is the oxygen value at the grid point xij at time tn = t0+nΔt, and NiNj are the total number of grid points. A numerically stable oxygen distribution was achieved when the normalized error reached a small enough value (εγn¯¯1010), where

εγn¯¯=εγnNiNj

An example of the numerically stable oxygen distribution is shown in Fig 2. The tissue morphology with 3.5% vascularity, tumor cell fraction of 55%, and stromal cellularity of 30% is presented in Fig 2A, and the final oxygen distribution in Fig 2B. The initial oxygen level was set up to γij0=0 mmHg uniformly in the whole tissue domain. The average oxygen level in the whole tissue stabilized at the level of 29.89 mmHg in about 2x104 iteration steps, reaching a normalized error of 9.99x10-11 (Fig 2C). The final stabilized oxygen level is independent of the oxygen concentration chosen to initiate this process (Fig B and Table A in S1 Text).

Fig 2. Stabilized oxygen distribution for an exemplary tissue morphology.

Fig 2

A. In silico tissue morphology comprised of 3.5% of vasculature (red circles), 55% of tumor cells (dark purple circles), and 30% of stromal cells (light pink circles). B. The stabilized oxygen distribution color-coded using the EPR imaging color scheme, with high oxygen levels (yellow) near the vessels and low oxygen levels (cyan) in poorly vascularized regions. C. Changes in the average oxygen concentration over time from initial 0 mmHg to the stable level of 29.89 mmHg.

Classification of tissues with specific saturation levels

The generated library contains 1,530 tumor tissues of different morphologies with a numerically stabile oxygen distribution. The minimum and maximum average pO2 values were achieved at the levels of 2.06 mmHg and 55.55 mmHg, respectively. All tumor tissues were divided into five classes according to their average pO2 (from 0 to 60 mmHg with increments of 12 mmHg).

The parameter space corresponding to each class is shown in Fig 3A in a form of a 3D convex hull, that is, the smallest convex set containing all data points from a given class (color-coded in blue, red, orange, yellow and white). Almost 1/3 of all tissues (506 cases) stabilized at a high level of 36–48 mmHg (yellow region). Moderate pO2 levels of 24–36 mmHg were achieved in 340 tissues (orange region). Low pO2 levels of 12–24 mmHg were reached in 284 tissues (red region), and a similar number of tissues (270) had hypoxic levels of 0–12 mmHg (blue region). The smallest number of tissues (130) reached a very high pO2 level, above 48 mmHg (white region). In general, the higher tissue vascularity and lower cellularity, the higher level of average tissue pO2. However, the vascularity and cellularity values need to be tightly balanced to achieve a desired level of pO2, which is illustrated by three examples in Fig 3B–3D. Each tissue reached an average pO2 level near 33 mmHg, although the increased tissue vascularity (from 1.5% to 2.5%, to 4%) is accompanied by increased total tissue cellularity (from 30% to 65%, to 95%). The time required for the pO2 levels to numerically stabilize is different in each case. Less dense tissues require more time (Fig 3B–3D last column), since it takes longer for the oxygen to reach sparsely located cells. Thus, initial changes in oxygen spatial distribution result mostly from diffusion, before cells start consuming oxygen contributing to the influx-outflux balance. We also analyzed how the numerically stabilized levels of oxygen depend on the random locations of vessels and cells by generating 25 different tissues with vascularity and cellularity corresponding to those in Fig 3B–3D. They stabilized at the levels of 32.63, 29.98, and 36.15 mmHg, respectively, with a standard deviation of 2–3 mmHg (Fig C in S1 Text).

Fig 3. Classification of tissue oxygenation.

Fig 3

A. A parameter space (convex hulls) of tissues characterized by vascularity, tumor cellularity and stromal cellularity classified into five classes with respect to the stabilized average oxygen level. For every tissue characteristic only one tissue morphology was included. B-D. Three examples of tissues with similar oxygen saturation levels: B. A tissue with vascularity 1.5%, tumor cellularity 15%, stromal cellularity 15%, and stable oxygen of 33.43 mmHg. C. A tissue with vascularity 2.5%, tumor cellularity 30%, stromal cellularity 35%, and stable oxygen of 33.53 mmHg. D. A tissue with vascularity 4%, tumor cellularity 75%, stromal cellularity 20%, and stable oxygen of 33.16 mmHg.

Selection of tissues best fitted to experimental data

For further analysis, we selected computational tissues with stabilized oxygen levels that closely matched the maximum experimental measurement recorded in each of the four ROIs from Fig 2 in[6]. In particular, region #1 (black) has an initial pO2 of 36.312 mmHg, and the generated tissue with the pO2 closest to it, 36.315 mmHg, contains a vascular fraction of 4%, tumor cell fraction of 15%, and stromal cell fraction of 75% of the tissue area (Fig 4A). The experimental region #2 (red) has a maximum pO2 of 22.89 mmHg, and our in silico tissue configuration with a vascular fraction of 2.5%, tumor fraction of 45%, and stromal fraction of 40% reached oxygenation of 22.22 mmHg (Fig 4B). The third experimental region (blue) has a pO2 of 13.99 mmHg, while the computational tissue with a numerically stabilized oxygen level of 14.01 mmHg contains a vascular fraction of 1.5%, tumor fraction of 40%, and stromal fraction of 45% of the tissue area (Fig 4C). Finally, the fourth experimental region (magenta) has a maximum pO2 near 1.83 mmHg, and the closest generated configuration has an oxygenation level of 2.06 mmHg and a vascular fraction of 0.5%, tumor fraction of 20%, and stromal fraction of 75% of the tissue area (Fig 4D).

Fig 4. Reconstruction of oxygen fluctuations in ROIs #1–4.

Fig 4

Tissue configurations (top row) for which numerically stabilized oxygen distributions matched the maximum average pO2 level in each of the region of interests and the reconstructed pO2 fluctuations when either vascular influx rates (middle row) or cellular uptake rates (bottom row) were varied. Straight lines connect experimental data recorded every 3 minutes. Blue triangles (top, influx) and red stars (bottom, uptake) denote computational data recorded each minute. Tissue characteristics: A. ROI#1 (black): vascularity 4%, tumor cellularity 15%, and stromal cellularity 75%. B. ROI#2 (red): vascularity 2.5%, tumor cellularity 45%, and stromal cellularity 40%. C. ROI#3 (blue): vascularity 1.5%, tumor cellularity 40%, and stromal cellularity 45%. D. ROI#4 (magenta): vascularity 0.5%, tumor cellularity 20%, and stromal cellularity 75%.

For each case, our goal was to reproduce the oxygen fluctuations shown in Fig 2 from [6]. Our approach was to alter either the oxygen influx rates or the oxygen cellular uptake rates every three minutes to match each data point that was recorded in in vivo experiments. Since the fluctuations in the four selected regions have different magnitudes, this would allow us to assess whether the given mechanism may be responsible for the observed changes in tissue oxygen levels. Once these rates were determined for the selected in silico tissues, we applied the same schedules to a set of tissues that stabilized at the similar oxygen levels to show how robust these optimal schedules are in reproducing oxygen fluctuations.

Reconstruction of experimentally measured oxygen fluctuations

To test the impact of vascular supply on tissue oxygenation, we simultaneously adjusted the vascular influx of oxygen in each vessel by assigning a fraction δV(t) (between 0 and 1) of the default maximum influx value γmax. To test the role of tumor cell metabolism on tissue oxygenation, we adjusted cellular uptake in all tumor cells by multiplying the default absorption value Tmax by a constant ratio δT(t) (between 0 and 50) to account for either decreased or increased cellular uptake. The rates δV(t) and δT(t) were determined using the Mesh Adaptive Direct Search (MADS) method as implemented in MATLAB® by the patternsearch routine[27]. This optimization algorithm utilizes a value calculated at a given time point by a simulation of the underlying deterministic system and does not require derivatives of the objective function.

Our optimization goal was to minimize the difference between the average tissue pO2 level recorded experimentally, γE(tk)¯, and the one computed by our model, γC(tk)¯, at the end of each 3-minute interval (i.e., for tk∈{4, 7, 10, 13, 16, 19, 22, 25, 28} minutes, N = 9 intervals in total), where x(tk−1) is a value of either the vascular influx rate δV(tk−1) or the tumor cell uptake rate δT(tk−1) at the beginning of each 3-minute time interval (i.e., for tk−1∈{0, 4, 7, 10, 13, 16, 19, 22, 25} minutes):

mink=1N|γE(tk)¯γC(tk)¯|x={x(t0),,x(tN1)}

Once the final optimal schedule (influx or uptake) is determined, the normalized L2-norm L2¯¯ between the simulated and experimental data points is reported as an indication of the goodness of fit (GoF) of the optimal schedule:

L2(γopt)¯¯=1Nk=1N(γE(tk)¯γopt(tk)¯)2

The optimal influx and uptake rates together with the normalized L2-norms for all ROIs are listed in the Table 2. Method convergence for the cases with best and worst GoF (both from ROI#1) is shown in Fig D in S1 Text.

Table 2. Influx and Uptake Schedules for four considered ROIs.

Time intervals GoF
0–4 4–7 7–10 10–13 13–16 16–19 19–22 22–25 25–28 L2(γopt)¯¯
Region #1 Black
Influx δV(t) 1 0.832 0.096 0.592 0.410 0.857 0.363 0.602 0.711 0.0013
Uptake δT(t) 1 4.625 50 15.75 50 4.125 50 14.875 9 0.9078
Region #2 Red
Influx δV(t) 0.84 0.709 1 0.1875 0.432 0.850 0.799 0.7168 0.887 0.0754
Uptake δT(t) 1.875 3.125 0.875 50 14.25 1.875 2.25 3 1.165 0.1986
Region #3 Blue
Influx δV(t) 1 0.598 0.676 0.729 0.908 0.629 0.787 1 0.832 0.0757
Uptake δT(t) 1 6.375 4.375 3.375 1.5 5.375 2.625 0.875 2.125 0.0779
Region #4 Magenta
Influx δV(t) 0 0.738 0.762 0.121 0 0.926 0 0 0 0.0003
Uptake δT(t) 50 6.875 6 50 50 2 50 50 50 0.1769

The resulting simulated fluctuations are shown in Fig 4, and the exemplar oxygen distributions at each stage are shown in Fig D in S1 Text. The presented results indicate that changes in vascular influx can reproduce experimentally observed fluctuations in pO2 levels in all four ROIs (the normalized L2-norms are below 0.1 in all cases). In the case of ROI#3, these influx alterations are moderate, not exceeding 40%. However, the sudden drops in pO2 level observed in ROI#1 and ROI#2 requires a substantial decrease in oxygen influx, as much as 80% and 99%, respectively. In the case of ROI#4, when the pO2 level reaches a value near 0, the oxygen influx must be completely shut down. These changes in intravascular oxygen content are physiologically plausible, as cases with low or even zero arterial oxygen supply (anoxemia) have been observed[28]. Here, we showed that short-term fluctuations in tissue oxygenation can be achieved by temporal alterations in intravascular oxygen supply.

The changes in tumor cell metabolisms (modeled as an increase in oxygen uptake) can explain smaller fluctuations in tissue oxygenation (ROI#3, the normalized L2-norm below 0.1). It required up to 6-fold changes in the cellular uptake rate to match these fluctuations. This mechanism can also fit cases with near-zero oxygen depletion in the whole tissue patch (ROI#4 and ROI#2, with L2-norms near 0.2). However, it failed to reproduce large (more than 5-fold) and rapid fluctuations (ROI#1, with normalized L2-norm near 1), even considering changes in cellular uptake of up to 50-fold. Thus, in general, oxygen fluctuations were not captured by changes in cell metabolism.

Robustness of optimal schedules

The optimal influx/uptake schedules described above were determined using four particular tissues for which the average oxygen level has stabilized at values closest to the maximum value recorded for each of the four ROIs from Fig 2 in[6]. Here, we investigated whether these optimal schedules applied to other tissues will reproduce oxygen fluctuations recorded experimentally. One motivation was to test whether tissues of various morphologies but similar average pO2 levels will respond in a similar way to the schedules that were optimized using one of these tissues. If fluctuations in the average pO2 level are not sensitive to tissue morphology, any of these tissues or a small subset of these tissues can be used for further simulation studies of diffusive therapeutic agents and their impact on tumor progression. Another motivation was to provide a link between the average data value recorded for radiologic image voxels and the structure of the corresponding tissues. Potentially, a very large number of tissue structures may result in the same average pO2 level. Our goal here was to investigate whether additional information, such as temporal data recorded for the same voxel, will result in a reduced number of tissue morphologies that reproduce that data. If this tissue number is smaller, we can determine better conditions for selection of tissue morphologies for further studies of intratumoral drug or biomarker distribution. Taken together, we can identify which mechanisms can reproduce the experimentally observed fluctuations, and to provide criteria for selection of different tissues for which these fluctuations can be reproduced.

To achieve our goals, we first identified four sets of tissues with oxygen levels that stabilized within +/- 3.5 mmHg of the maximum value recorded for each ROI (#1-black, #2-red, #3-blue, and #4-magenta). The number of such representative tissues is listed in Table 3 for each ROI. Next, we applied the optimal influx schedules that were determined for each ROI to the corresponding set of representative tissues. Separately, we also applied the optimal uptake schedules to these tissues. To measure how well the applied schedules reproduced the experimentally observed oxygen fluctuations, we recorded the normalized L2-norms (L2(γopt)¯¯), as described above. The total number of tissues considered and the numbers of tissues with L2-norms below a threshold value of 0.2 are listed in Table 3 for each ROI.

Table 3. Number of tissues representing each ROI and tissues fitting each fluctuation.

Number of representative tissues: ROI#1 ROI#2 ROI#3 ROI#4
within +/- 3.5 mmHg from experimental value 277 189 147 123
with L2-norm<0.2 for the influx schedule 42 38 40 61
with L2-norm<0.2 for the uptake schedule 0 6 15 73

The obtained results are also summarized graphically in Fig 5. The convex hulls represent a range of tissue characteristics (i.e., vascularity, tumor cellularity, and stromal cellularity) that satisfy a particular condition under consideration. The cyan convex hulls in Fig 5A represent all tissues with the oxygen level that stabilized within +/- 3.5 mmHg of the maximum value recorded for each ROI. A subset of tissues for which the optimal influx schedule resulted in oxygen fluctuations that fitted the experimental data with a normalized L2-norm below 0.2 are shown as green convex hulls. Similarly, a subset of tissues for which the optimal uptake schedule fitted the experimental data with the L2-norm below 0.2 are shown in black. The scatter plots in Fig 5B show the relationship between the initial numerically stable pO2 (the x-axis shows the deviation of the simulated pO2 level from the experimental measurement) and the normalized L2-norm value for each tissue (y-axis). The green dots represent data for the optimal influx schedule and grey dots show data for the optimal uptake schedule. The red dashed lines represent the normalized L2-norm value of 0.2.

Fig 5. Robustness of optimal influx and uptake schedules.

Fig 5

A. Parameter spaces of all tissues with oxygen levels within +/- 3.5 mmHg of the maximum experimental value for each ROI; 3D convex hulls shown in cyan, together with convex hulls for optimal influx schedule (green) and optimal uptake schedule (black) that fit experimental data with normalized L2-norm smaller than 0.2. B. Normalized L2-norms for influx schedule (green dots) and uptake schedule (grey dots) for each tissue from the cyan convex hull. The red dashed line represents the L2-norm value of 0.2. The results are shown from left to right for: ROI#1 (black), ROI#2 (red), ROI#3 (blue), and ROI#4 (magenta).

In general, the closest the simulated stabilized oxygen level is to that measured experimentally, the more successful the optimal influx schedule is, since all green dots located below the red threshold line are concentrated near the 0 value in Fig 5B. These tissues are also co-localized in Fig 5A, although the tissue characteristics shown as the green convex hulls span a broader range of values. The exception is ROI#4, for which almost all considered tissues responded to influx and uptake schedules by following the experimental fluctuations (the green and black convex hulls almost overlap with the cyan one). The fluctuations in this region were very small, so they were easier to reproduce by both schedules. As oxygen fluctuations increased (from ROI#3 to ROI#2, to ROI#1), the numbers of representative tissues that followed the experimental data was decreased, and there was no tissue in ROI#1 for which the optimal cellular uptake schedule resulted in fitting with the normalized L2-norm below 0.2 (no black convex hull).

Several interesting observations can be made based on these results. We showed that only a fraction of the tissue morphologies with oxygen levels that stabilized near the given experimental data are able to reproduce temporal changes in tissue pO2 when the vascular influx of oxygen is varied. These well-fitted tissues have numerically stabile pO2 levels within +/- 1mmHg of the experimental data. Thus, for future applications we can reduce the searching radius from 3.5 to 1 mmHg in order to find plausible tissue morphologies.

By comparing simulation results with the vascular influx schedule vs. the cellular uptake schedule, we conclude that alterations in vascular oxygen levels were able to reproduce the observed fluctuations. On the other hand, in order to achieve the same effect when the metabolic changes in tumor cells are considered, the cells would need to increase their oxygen absorption by 50-fold over a span of 3 minutes, which may not be biologically feasible. While it has been reported in the literature that cellular oxygen uptake can vary greatly between cell lines (i.e., 1–350 amol/s per cell[29], and 1–120 amol/s per cell[30]), changes reported in the same cells varied no more than 10-fold when the culture conditions were modified[14,31].

Discussion

Motivated by published experimental data that showed frequent fast fluctuations in tissue oxygenation (as high as 30 mmHg over 3-minute intervals), we investigated plausible biological mechanisms that could explain these results. The first hypothesis we tested was that pO2 fluctuations are related to changes in vascular oxygen supply. We generated a large number of in silico tumor morphologies and selected those for which numerically stable pO2 levels were the closest to the experimental data in each region of interest (ROI). Next, we used computational optimization techniques to determine influx schedules that best fitted the experimental fluctuation data. Finally, we applied these optimal schedules to other tissues with similar pO2 levels to test whether they will respond in a similar way to the same influx schedules. This procedure showed that rapid changes in vascular oxygen supply can explain the fluctuations observed in[6] in all considered ROIs.

However, the same mouse experiments showed no differences in the intensity of an EPR-specific imaging tracer in the same ROIs. Since this tracer is supplied intravenously but is not absorbed by the cells, this suggested that blood flux in the tumor vasculature is steady and that the pO2 fluctuations may be a result of increased oxygen uptake by the tumor cells. Therefore, we also tested the hypothesis that modulations in cellular oxygen absorption are responsible for the observed pO2 fluctuations within the tissue. Using the same set of in silico tissues, and applied computational optimization techniques to determine most optimal uptake schedules that fitted the experimental fluctuation data. Again, we applied these optimal schedules to other tissues with similar pO2 levels to test schedule robustness. This procedure showed that in order to fit fluctuations with more than 5-fold magnitude, the 50-fold changes in cellular oxygen absorption would have to occur over 3-minute intervals, which may not be biologically feasible. Thus, we showed computationally that changes in oxygen influx are the most probable explanation of cyclic hypoxia observed in EPR imaging experiments reported in[6].

Moreover, we provided a link between the average data value recorded by radiologic images and the cellular/vascular architecture of the tumor tissue. Since a cross section of a single EPR voxel has an area about a millimeter square, the underlying tissue patch is large enough to contain subregions of different characteristics. For example, it may include zones with no vasculature, with severe hypoxia, or high cellular density that is poorly penetrated by drugs, or may harbor resistant tumor cell subpopulations. Such cellular-scale phenomena will not be reflected in the average values reported by radiologic images. To capture information on the cellular scale based on average values novel computational approaches are needed. Potentially, a very large number of tissue architectures may result in the same average pO2 level. However, by adding a series of temporal data recorded for the same voxel, we showed that the number of tissue morphologies capable of reproducing the underlying temporal dynamics of oxygen is greatly reduced. In the cases discussed here, we were left with about 40 different tissues for each ROI out of over 1,500 distinct tissues generated initially. This remaining number of tissues is computationally manageable for any further analysis or simulations, giving us a tool for microscale modeling (at the individual cell level) based on macroscale data (average value in tissue voxel).

The model presented here was developed with some simplified assumptions. All vessels in the model are of the same size and contain identical levels of oxygen. Similarly, all tumor cells are of the same size, as are the stromal cells. This was done to reduce model complexity, since the spatial variations in tissue morphology (vascular, tumor and stromal fractions) already introduced a fair amount of heterogeneity. However, in future research, we will incorporate variable sizes of structural tissue elements, as well as non-uniform oxygen influx and consumptions rates in tumor and various stromal cells. It was discussed in[6] that oxygen fluctuations are correlated with local vascular functionality within the tumor. While currently this is not included, in future applications we can add a possibility to model whether the vasculature is patent. In addition, the voxels of radiologic images are volumetric, and we only model the 2D voxel cross section here. Our model can be adapted to full 3D space and can incorporate 3D spatial heterogeneities. All mathematical equations, both the agent-based model rules and the reaction-diffusion equation for oxygen kinetics, can be easily extended to a 3D space. Tumor and stromal cells can be represented as spheres (as we have done in[11,32] and others were reviewed in[33,34]), and tumor vasculature as collections of branched tube segments (as in[35,36,37] and in models reviewed in[33,34]). The only difficulty in 3D models is in visualization of irregular patterns of diffused oxygen and in the time required to complete these simulations, since smaller time steps may be needed to assure computational code stability and convergence.

To our knowledge, this is the first model that generates tissue morphologies corresponding to voxels of radiologic images. The topic of connecting radiology and histology images is of increasing interest since cellular-resolution images harbor detailed information about tumor composition, spatial heterogeneities, and molecular or metabolic landscapes. However, histology samples are collected from tumor biopsies or resections, and thus can only be acquired a limited number of times. In contrast, radiologic images provide non-invasive longitudinal information of tumor states and responses to treatments. Several co-registration methods between these two imaging modalities have recently been developed[3840]. While mathematical modeling has been previously used in connection with radiologic images[4146], only continuous models were utilized. Several different agent-based models were, in turn, used to model analogues of in vivo tumor histology[4750], but were not extended to radiologic imaging data. Fluctuations in the tumor microenvironment have been addressed in the context of long-term evolutionary dynamics, but have not compared to experimental data[51,52].

While we used pre-clinical data collected using EPR imaging here, our goal for future studies is to develop a similar macro-scale to micro-scale model based on clinically-relevant radiologic imaging. Several different minimally invasive imaging tests can be used for longitudinal monitoring of tumor response to therapies, such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET). Of particular interest to our studies are methods that can provide additional information related to tissue structure or oxygen/drug pharmacokinetics. The dynamic contrast-enhanced MRI (DCE-MRI) can capture temporal information on tissue perfusion, microvascular permeability, vascular volume fraction, extracellular-extravascular volume fraction, and diffusivity of tissue water, which, combined, can predict outcomes and guide therapy[53,54]. To augment temporal resolution, new under-sampling techniques coupled with parallel imaging methods (GRASP, Golden-angle Radial Sparse Parallel imaging) can be used to continuously acquire images over a long-term continuum (i.e. 5 minutes) at repeatable, small time intervals (i.e. 2.5 seconds), generating a detailed library of exquisitely time-resolved data[55]. Two other non-invasive imaging approaches, TOLD MRI (Tissue Oxygenation Level Dependent MRI) and BOLD MRI (Blood Oxygenation Level Dependent MRI), can be used to visualize information on tumor oxygenation and vascular hemodynamics[56,57]. This additional information at a voxel level can be used to reduce the number of representative tissue morphologies in our micro-macro scale mechanistic link for cell-scale simulations of various anti-cancer treatments (e.g., chemotherapy, hypoxia-activated targeted therapy, radiotherapy, or immunotherapy). These microscopic-level predictions can be compared to longitudinal radiologic data on a tissue voxel scale. This can give us an insight into heterogeneities of intratumoral drug distributions or immune cell penetration patterns, and on the emergence of tissue subregions that can harbor chemo-, or radio-resistant cells. Thus, the mechanistic models of the tumor, such as the one we have described here, will enable patient-specific simulations to predict the trajectory of tumor response to specific interventions.

Supporting information

S1 Text. This supporting information includes the computational procedure for resolving cell overlaps, discussion on the choice of model parameters, description of an algorithm for stabilizing oxygen gradient, and details of the optimization protocol used for fitting experimentally observed fluctuations.

Fig A. Resolving cell overlapping conditions using repulsive forces. A left-top quarter of the tumor tissue domain characterized by 2% vascularity, 30% tumor cellularity, and 35% stromal cellularity with tumor cells represented by purple circles, stromal cells as pink circles, and vessels as red circles. A. An initial iteration 0 before repulsive forces are applied, showing overlapping cells and vessels. B. By iteration 25, repulsive forces have been applied and cell relocation has begun; only some cells remained overlapped. C. In iteration 100, all overlapping conditions have been resolved and cell positions have stabilized to reflect no overlapping. We allow vessels to overlap to represent irregular vessels shapes often seen in histology images.Fig B. Oxygen stabilization within the tumor tissue and the role of initial oxygen concentration. A-D. Snapshots showing oxygen distribution during the stabilization process, at iterations 0, 2000, 10000, and 18970. E. Temporal evolution of the average oxygen level from 0 mmHg until is stabilizes at the 29.89 mmHg with the stabilization error below 10−10. F. Tissue morphology with 3.5% vascular fraction, 55% tumor cellularity, and 30% stromal cellularity; vessels are represented by red circles, tumor cells by purple circles, and stromal cells by pink circles. G. Temporal evolution of average oxygen levels for 21 simulations of the same tissue shown in F. Each simulation is indicated by a different color that corresponds to initial uniform tissue oxygenation. All simulations stabilized around the 29.89 mmHg, however, simulations with lower initial oxygen concentrations have stabilized faster (cyan and blue lines) than those that started with higher initial oxygen concentrations (red and yellow lines). Table A. Initial tissue oxygenation vs. final stabilized oxygen level. Stabilized average oxygen levels for tissue of characteristics: 3.5% vascular fraction, 55% tumor cellularity, and 30% stromal cellularity, and initial uniform oxygen concentration reported as % of the maximal value of 60 mmHg. The stabilized oxygen levels units: mmHg. Fig C. Analysis of oxygen stabilization for tissues of identical characteristics but different morphologies. A. Levels of oxygen stabilization for 25 tissues of vascularity: 1.5%, tumor cellularity: 15%, stromal cellularity: 15%, with an average oxygenation level of 32.63 mmHg +/- 3.3 mmHg. B. Levels of oxygen stabilization for 25 tissues of vascularity: 2.5%, tumor cellularity: 30%, stromal cellularity: 35%, with an average oxygenation level of 29.98 mmHg +/- 2.4 mmHg. C. Levels of oxygen stabilization for 25 tissues of vascularity: 4%, tumor cellularity: 75%, stromal cellularity: 20%, with an average oxygenation level of 36.15 mmHg +/- 2.4 mmHg. D. Spatial gradient of oxygen with lowest average level among tissues in A. E-I. Spatial gradients of oxygen with highest (left) and lowest (right) average levels among tissues considered in A-C. Fig D. Convergence of the MABS method for influx and uptake schedules for ROI #1 (black). A. Experimental fluctuations (solid line) and simulated fluctuations (blue triangles) for the influx schedule with corresponding oxygen distributions at each time point (above the arrows). An inset shows tissue morphology. B. The convergence graphs for each of the 8 time segments with the converging influx rates (red pins) and the converging objective function values (blue pins). C. Experimental fluctuations (solid line) and simulated fluctuations (red stars) for the uptake schedule with corresponding oxygen distributions at each time point (above arrows). D. The convergence graphs for each of the 8 time segments with the converging uptake rates (red pins) and the converging objective function values (blue pins).

(DOCX)

Data Availability

The computational code is deposited at GitHub: https://github.com/rejniaklab/MultiCell-O2-fluctuations.

Funding Statement

This work was supported in part by the U01-CA202229 Physical Sciences Oncology Project (PS-OP) grant from the US National Institutes of Health, National Cancer Institute (to KR), the Moffitt Radiology Pilot Project grant (to JC), and Shared Resources at the H. Lee Moffitt Cancer Center & Research Institute an NCI designated Comprehensive Cancer Center under the grant P30-CA076292 from the National Institutes of Health (Moffitt IRAT Core, to NR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–87. Epub 2012/11/15. doi: 10.1038/nrclinonc.2012.171 . [DOI] [PubMed] [Google Scholar]
  • 2.Harris LH. Hypoxia-a key to rgulatory factor in tumour growth. Nature Reviews Bacer. 2002;2:38–47. doi: 10.1038/nrc704 [DOI] [PubMed] [Google Scholar]
  • 3.Saxena K, Jolly K. Acute vs. Chrinic vs. Cyclic Hypoxia: Their differentual dynamics, molecular mechanisnsm and effects on tumor progression. Biomolecules. 2019;9:339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Michiels C, Tellier C, Feron O. Cycling hypoxia: A key feature of the tumor microenvironment. Biochim Biophys Acta. 2016;1866(1):76–86. Epub 2016/06/28. doi: 10.1016/j.bbcan.2016.06.004 . [DOI] [PubMed] [Google Scholar]
  • 5.Dewhirst M, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response Nat Rev Cnacer. 2008;8(6):425–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Yasui H, Matsumoto S, Devasahayam N, Munasinghe JP, Choudhuri R, Saito K, et al. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res. 2010;70(16):6427–36. doi: 10.1158/0008-5472.CAN-10-1350 ; PubMed Central PMCID: PMC2922437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Matsuo M, Matsumoto S, Mitchell JB, Krishna MC, Camphausen K. Magnetic resonance imaging of the tumor microenvironment in radiotherapy: perfusion, hypoxia, and metabolism. Semin Radiat Oncol. 2014;24(3):210–7. Epub 2014/06/17. doi: 10.1016/j.semradonc.2014.02.002 ; PubMed Central PMCID: PMC4060050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Colliez F, Gallez B, Jordan BF. Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical Settings. Front Oncol. 2017;7:10. Epub 2017/02/10. doi: 10.3389/fonc.2017.00010 ; PubMed Central PMCID: PMC5263142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Matsumoto K, Subramanian S, Devasahayam N, Aravalluvan T, Murugesan R, Cook JA, et al. Electron paramagnetic resonance imaging of tumor hypoxia: enhanced spatial and temporal resolution for in vivo pO2 determination. Magnetic resonance in medicine. 2006;55(5):1157–63. Epub 2006/04/06. doi: 10.1002/mrm.20872 . [DOI] [PubMed] [Google Scholar]
  • 10.Perez-Velazquez J, Rejniak KA. Drug-Induced Resistance in Micrometastases: Analysis of Spatio-Temporal Cell Lineages. Front Physiol. 2020;11:319. Epub 2020/05/05. doi: 10.3389/fphys.2020.00319 ; PubMed Central PMCID: PMC7180185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Karolak A, Poonja S, Rejniak KA. Morphophenotypic classification of tumor organoids as an indicator of drug exposure and penetration potential. PLoS Comput Biol. 2019;15(7):e1007214. Epub 2019/07/17. doi: 10.1371/journal.pcbi.1007214 ; PubMed Central PMCID: PMC6660094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Elas M, Bell R, Hleihel D, Barth ED, McFaul C, Haney CR, et al. Electron paramagnetic resonance oxygen image hypoxic fraction plus radiation dose strongly correlates with tumor cure in FSa fibrosarcomas. Int J Radiat Oncol Biol Phys. 2008;71(2):542–9. Epub 2008/05/14. doi: 10.1016/j.ijrobp.2008.02.022 ; PubMed Central PMCID: PMC2577780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Christodoulou AG, Redler G, Clifford B, Liang ZP, Halpern HJ, Epel B. Fast dynamic electron paramagnetic resonance (EPR) oxygen imaging using low-rank tensors. J Magn Reson. 2016;270:176–82. Epub 2016/08/09. doi: 10.1016/j.jmr.2016.07.006 ; PubMed Central PMCID: PMC5127203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wojtkowiak JW, Cornnell HC, Matsumoto S, Saito K, Takakusagi Y, Dutta P, et al. Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302. Cancer Metab. 2015;3(1):2. Epub 2015/01/31. doi: 10.1186/s40170-014-0026-z ; PubMed Central PMCID: PMC4310189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhang J, Zhang Q. Using Seahorse Machine to Measure OCR and ECAR in Cancer Cells. In: Haznadar M, editor. Cancer Metabolism: Springer; 2019. p. 353–63. [DOI] [PubMed] [Google Scholar]
  • 16.NCI-60 Human Tumor Cell Lines Screen [Internet]. 2015. Available from: https://dtp.cancer.gov/discovery_development/nci-60/.
  • 17.Shashni B, Ariyasu S, Takeda R, Suzuki T, Shiina S, Akimoto K, et al. Size-Based Differentiation of Cancer and Normal Cells by a Particle Size Analyzer Assisted by a Cell-Recognition PC Software. Biol Pharm Bull. 2018;41(4):487–503. doi: 10.1248/bpb.b17-00776 . [DOI] [PubMed] [Google Scholar]
  • 18.Caramalho I, Faroudi M, Padovan E, Müller S, Valitutti S. Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation. J Cell Mol Med. 2009;13(9B):3834–46. doi: 10.1111/j.1582-4934.2008.00586.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rieger H, Fredrich T, Welter M. Physics of the tumor vasculature: Theory and experiment. Eur Phys J Plus. 2016;131:31. [Google Scholar]
  • 20.Baumgartner W, Drenckhahn D. Transmembrane cooperative linkage in cellular adhesion. Eur J Cell Biol. 2002;81(3):161–8. doi: 10.1078/0171-9335-00233 . [DOI] [PubMed] [Google Scholar]
  • 21.Rejniak K, Dillon RH. A single cell-based model of the ductal tumour microarchitecture. Computational and Mathematical Methods in Medicine. 2007;8(1):51–69. [Google Scholar]
  • 22.Shimolina LE, Izquierdo MA, Lopez-Duarte I, Bull JA, Shirmanova MV, Klapshina LG, et al. Imaging tumor microscopic viscosity in vivo using molecular rotors. Sci Rep. 2017;7:41097. doi: 10.1038/srep41097 ; PubMed Central PMCID: PMC5278387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Latour LL, Svoboda K, Mitra PP, Sotak CH. Time-dependent diffusion of water in a biological model system. Proc Natl Acad Sci U S A. 1994;91(4):1229–33. Epub 1994/02/15. doi: 10.1073/pnas.91.4.1229 ; PubMed Central PMCID: PMC43130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schornack PA, Gillies RJ. Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia. 2003;5(2):135–45. Epub 2003/03/28. doi: 10.1016/s1476-5586(03)80005-2 ; PubMed Central PMCID: PMC1502399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988;48(10):2641–58. Epub 1988/05/15. . [PubMed] [Google Scholar]
  • 26.Casciari J, Sotirchos S, Sutherland R. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. 1992;151(2):386–94. doi: 10.1002/jcp.1041510220 [DOI] [PubMed] [Google Scholar]
  • 27.Venkataraman P. Applied Optimization with MATLAB Programming Wiley; 2009. [Google Scholar]
  • 28.Sarkar M, Niranjan N, Banyal PK. Mechanisms of hypoxemia. Lung India. 2017;34(1):47–60. Epub 2017/02/02. doi: 10.4103/0970-2113.197116 ; PubMed Central PMCID: PMC5234199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wagner BA, Venkataraman S, Buettner GR. The rate of oxygen utilization by cells. Free Radic Biol Med. 2011;51(3):700–12. Epub 2011/06/15. doi: 10.1016/j.freeradbiomed.2011.05.024 ; PubMed Central PMCID: PMC3147247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Place TL, Domann FE, Case AJ. Limitations of oxygen delivery to cells in culture: An underappreciated problem in basic and translational research. Free Radic Biol Med. 2017;113:311–22. Epub 2017/10/17. doi: 10.1016/j.freeradbiomed.2017.10.003 ; PubMed Central PMCID: PMC5699948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Pavliv O, et al. Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort. PLoS One. 2014;9(1):e85436. Epub 2014/01/15. doi: 10.1371/journal.pone.0085436 ; PubMed Central PMCID: PMC3885720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kim M, Reed D, Rejniak KA. The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study. J Theor Biol. 2014;352:31–50. Epub 2014/03/13. doi: 10.1016/j.jtbi.2014.02.027 ; PubMed Central PMCID: PMC5483857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Chamseddine IM, Rejniak KA. Hybrid modeling frameworks of tumor development and treatment. Wiley Interdiscip Rev Syst Biol Med. 2020;12(1):e1461. Epub 2019/07/18. doi: 10.1002/wsbm.1461 ; PubMed Central PMCID: PMC6898741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Karolak A, Markov DA, McCawley LJ, Rejniak KA. Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J R Soc Interface. 2018;15(138). Epub 2018/01/26. doi: 10.1098/rsif.2017.0703 ; PubMed Central PMCID: PMC5805971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Boujelben A, Watson M, McDougall S, Yen YF, Gerstner ER, Catana C, et al. Multimodality imaging and mathematical modelling of drug delivery to glioblastomas. Interface Focus. 2016;6(5):20160039. Epub 2016/10/07. doi: 10.1098/rsfs.2016.0039 ; PubMed Central PMCID: PMC4992742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Secomb TW. A Green’s function method for simulation of time-dependent solute transport and reaction in realistic microvascular geometries. Math Med Biol. 2016;33(4):475–94. Epub 2015/10/08. doi: 10.1093/imammb/dqv031 ; PubMed Central PMCID: PMC5155623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ii S, Kitade H, Ishida S, Imai Y, Watanabe Y, Wada S. Multiscale modeling of human cerebrovasculature: A hybrid approach using image-based geometry and a mathematical algorithm. PLoS Comput Biol. 2020;16(6):e1007943. Epub 2020/06/23. doi: 10.1371/journal.pcbi.1007943 ; PubMed Central PMCID: PMC7332106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Jardim-Perassi BV, Huang S, Dominguez-Viqueira W, Poleszczuk J, Budzevich MM, Abdalah MA, et al. Multiparametric MRI and Coregistered Histology Identify Tumor Habitats in Breast Cancer Mouse Models. Cancer Res. 2019;79(15):3952–64. Epub 2019/06/13. doi: 10.1158/0008-5472.CAN-19-0213 ; PubMed Central PMCID: PMC6677627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Roodakker KR, Alhuseinalkhudhur A, Al-Jaff M, Georganaki M, Zetterling M, Berntsson SG, et al. Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity. Eur J Nucl Med Mol Imaging. 2019;46(3):569–79. Epub 2018/08/16. doi: 10.1007/s00259-018-4107-z ; PubMed Central PMCID: PMC6351509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Rusu M, Rajiah P, Gilkeson R, Yang M, Donatelli C, Thawani R, et al. Co-registration of pre-operative CT with ex vivo surgically excised ground glass nodules to define spatial extent of invasive adenocarcinoma on in vivo imaging: a proof-of-concept study. Eur Radiol. 2017;27(10):4209–17. Epub 2017/04/08. doi: 10.1007/s00330-017-4813-0 ; PubMed Central PMCID: PMC5630490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Jarrett AM, Hormuth DA, 2nd, Wu C, Kazerouni AS, Ekrut DA, Virostko J, et al. Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data. Neoplasia. 2020;22(12):820–30. Epub 2020/11/17. doi: 10.1016/j.neo.2020.10.011 ; PubMed Central PMCID: PMC7677708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Hormuth DA 2nd, Jarrett AM, Lima E, McKenna MT, Fuentes DT, Yankeelov TE. Mechanism-Based Modeling of Tumor Growth and Treatment Response Constrained by Multiparametric Imaging Data. JCO Clin Cancer Inform. 2019;3:1–10. Epub 2019/02/27. doi: 10.1200/CCI.18.00055 ; PubMed Central PMCID: PMC6535803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Jackson PR, Juliano J, Hawkins-Daarud A, Rockne RC, Swanson KR. Patient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practice. Bull Math Biol. 2015;77(5):846–56. Epub 2015/03/22. doi: 10.1007/s11538-015-0067-7 ; PubMed Central PMCID: PMC4445762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rockne RC, Trister AD, Jacobs J, Hawkins-Daarud AJ, Neal ML, Hendrickson K, et al. A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET. J R Soc Interface. 2015;12(103). Epub 2014/12/30. doi: 10.1098/rsif.2014.1174 ; PubMed Central PMCID: PMC4305419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Roque T, Risser L, Kersemans V, Smart S, Allen D, Kinchesh P, et al. 3-D Reaction-Diffusion Model of Solid Tumor Growth. IEEE proceedings. 2018:1–9. doi: 10.1109/TMI.2017.2779811 [DOI] [PubMed] [Google Scholar]
  • 46.Villa C, Chaplain MAJ, Lorenzi T. Modeling the emergence of phenotypic heterogeneity in vascularized tumors. arXiv. 2021:1–21. [Google Scholar]
  • 47.Curtis LT, Wu M, Lowengrub J, Decuzzi P, Frieboes HB. Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles. PLoS One. 2015;10(12):e0144888. Epub 2015/12/15. doi: 10.1371/journal.pone.0144888 ; PubMed Central PMCID: PMC4682796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Perez-Velazquez J, Gevertz JL, Karolak A, Rejniak KA. Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance. Adv Exp Med Biol. 2016;936:149–64. Epub 2016/10/16. doi: 10.1007/978-3-319-42023-3_8 ; PubMed Central PMCID: PMC5113820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Powathil GG, Swat M, Chaplain MA. Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. Semin Cancer Biol. 2015;30:13–20. Epub 2014/03/13. doi: 10.1016/j.semcancer.2014.02.003 . [DOI] [PubMed] [Google Scholar]
  • 50.Robertson-Tessi M, Gillies RJ, Gatenby RA, Anderson AR. Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. 2015;75(8):1567–79. Epub 2015/04/17. doi: 10.1158/0008-5472.CAN-14-1428 ; PubMed Central PMCID: PMC4421891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Ardaseva A, Gatenby RA, Anderson ARA, Byrne HM, Maini PK, Lorenzi T. A Mathematical Dissection of the Adaptation of Cell Populations to Fluctuating Oxygen Levels. Bull Math Biol. 2020;82(6):81. Epub 2020/06/20. doi: 10.1007/s11538-020-00754-7 . [DOI] [PubMed] [Google Scholar]
  • 52.Lorenzi T, Chisholm RH, Desvillettes L, Hughes BD. Dissecting the dynamics of epigenetic changes in phenotype-structured populations exposed to fluctuating environments. J Theor Biol. 2015;386:166–76. Epub 2015/09/17. doi: 10.1016/j.jtbi.2015.08.031 . [DOI] [PubMed] [Google Scholar]
  • 53.Stringfield O, Arrington JA, Johnston SK, Rognin NG, Peeri NC, Balagurunathan Y, et al. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme. Tomography. 2019;5(1):135–44. Epub 2019/03/12. doi: 10.18383/j.tom.2018.00052 ; PubMed Central PMCID: PMC6403044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lorza AMA, Ravi H, Philip RC, Galons JP, Trouard TP, Parra NA, et al. Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin. Sci Rep. 2020;10(1):14449. Epub 2020/09/04. doi: 10.1038/s41598-020-71246-w ; PubMed Central PMCID: PMC7468301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Feng L, Wen Q, Huang C, Tong A, Liu F, Chandarana H. GRASP-Pro: imProving GRASP DCE-MRI through self-calibrating subspace-modeling and contrast phase automation. Magn Reson Med. 2020;83:94–108. doi: 10.1002/mrm.27903 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Hallac RR, Zhou H, Pidikiti R, Song K, Stojadinovic S, Zhao D, et al. doi: 10.1002/mrm.24846 Magnetic resonance in medicine. 2014;71(5):1863–73. Epub 2013/07/03. PubMed Central PMCID: PMC3883977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Landowski TH, Guntle GP, Zhao D, Jagadish B, Mash EA, Dorr RT, et al. Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol. 2016;9(3):228–35. Epub 2016/05/17. doi: 10.1016/j.tranon.2016.04.007 . [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009206.r001

Decision Letter 0

Philip K Maini, Feilim Mac Gabhann

1 Apr 2021

Dear Dr. Rejniak,

Thank you very much for submitting your manuscript "Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations" for consideration at PLOS Computational Biology.

As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Philip K Maini

Associate Editor

PLOS Computational Biology

Feilim Mac Gabhann

Editor-in-Chief

PLOS Computational Biology

***********************

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: review uploaded as an attachment

Reviewer #2: The manuscript by Kingsley et al. presents a computational investigation into the cause of small-scale oxygen fluctuations in solid tumours. An agent-based model is used to generate a set of micro-scale tissue morphologies which emulate voxel-scale O2 gradients observed in squamous cell carcinoma VII (SCCVII) in vivo, using electron paramagnetic resonance imaging (EPRI; data from Yasui et al. (2010)). Using this framework, the authors showed that changes in intravascular O2 reproduce the magnitude of fluctuations in vivo whereas modifying cellular absorption did not.

The written language of the manuscript was at times fragmented which hindered readability but I enjoyed the novelty of generating an agent-based modelling framework to infer plausible explanations of in vivo observations. That said, I have significant reservations regarding the model’s application to EPRI data which may impact the biological conclusions of the manuscript.

In the Supplementary Material the authors state that the “model represents features characteristic of many solid tumors, thus we did not focus on any specific tumor type”. I agree. The modelling framework can, to an extent, represent certain features of solid tumours. However, not focusing on tumour type in this manuscript when attempting to recreate pO2 fluctuations observed by Yasui et al. (2010) (Fig. 1 in Kingsley et al.) in SCVII tumours, I believe, is an error. Tumour microenvironment heterogeneity can vary wildly between tumour types and so by not targeting SCVII tumours may negate the authors' biological inferences.

To mimic the fluctuations and magnitudes in O2 observed by Yasui et al. (2010) in silico, the authors should (where possible) parameterise their models with respect to SCCVII tumours. For example, Kingsley et al. used a constant vessel diameter of 40 microns, yet SCVII have diameters in the range of 14.5 – 11.0 microns for tumours of similar masses [1] (see Fig. 23 in [1]). The authors here also increment tissue vascularity from 0.5 to 5%. However, Yasui et al. (2010) reports vascular density of 27.7 ± 2.1% and 8.1 ± 1.0% for small and large SCVII tumours, respectively. Similarly, [1] reports vascular density as between 2 – 7.5% for large SCVII tumours (see Fig. 25 in [1]). Generating new tissue morphologies with these reported values may not change the authors’ conclusion regarding cycling hypoxia but will clearly alter the range of morphologies which replicate experimentally observed pO2 fluctuations.

In general, the manuscript would benefit from relating its conclusions back to the study of Yasui et al. (2010) in terms of the additional insights the in silico model provides. For example, Kingsley et al. indicate that upstream effects (via varying vessel influx levels) replicate O2 gradients observed in the EPRI data. Comparatively, using analysis of the SCVII tumours via immunohistochemistry, Yasui et al. (2010), pO2 fluctuations correlated with pericyte density (i.e., local vascular functionality) rather than vascular density. Kingsley et al. could use their model to indict whether this hypothesis may be true, whilst highlighting that it does not currently include local vascular functionality but has the scope to in the future.

Presenting the generalised modelling framework and then applying it to the EPRI data to make conclusions regarding SCVII tumours I believe would really elevate the manuscript.

The following are further points which could improve the manuscript:

1. There are several places in the manuscript where I would expect a reference to support a written statement but one is not given. For example, Line 76 regarding oxygen gradients at 120-180 um from the vasculature.

2. The introduction dives straight into discussing the ROIs observed in Yasui et al. (2010). However, a brief explanation of how EPRI works along with spatial information such as EPRI resolution in comparison to microenvironment features in the authors’ tissue morphologies. This would develop the reader’s understanding from the start of the limitations of EPRI and how the manuscript seeks to link the micro- and macro-scales.

3. Lines 126 and 491, voxel dimensions are defined as mm2 – voxels are volumetric.

4. Following (3), the authors do not discuss the fact that the model is 2-dimensional (although not explicitly stated) yet EPRI is 3-dimensional. From Yasui et al. (2010), I assume that the ROIs from are 3-dimensional ROIs and that plot of changes in pO2 (Fig 2c) is an average for a given ROI? This should be stated and highlighted that the current model does not incorporate 3D spatial heterogeneities.

5. The authors discuss “large” fluctuations in tumour oxygenation. It would be useful to write in-text what the authors consider as large (i.e., magnitude).

6. Line 165 to 166 state that vessels can overlap to represent shapes observed in histological slices and that further information of the algorithm is provided in Supporting Information S1. However, the only indication of overlapping vessels is in Fig S3f. Further, examples of overlapping vessels with similar images of these shapes in histological images would be useful. In addition, where vessels with multiple overlaps as in Fig Sf (see 3 overlapping vessels in the bottom left-hand corner) excluded from the library of tissue samples? I imagine these shapes are not observed in histology and so should be omitted.

7. Lines 507 to 534 in the Discussion reads like a literature review of imaging methods to observe tissue oxygenation. It is odd that this forms a significant portion of the Discussion.

8. A discussion of the model limitations of the model / future development (heterogeneous vasculature and O2 influx, 3D etc) the Discussion would be very useful.

9. It would be advisable to use colour blind safe colour schemes for the figures.

10. In Fig 4., the iteration subfigures on the right-hand side may be presented better on a log x-axis.

11. In Fig 5., the subfigures showing oxygen vs. time should be rescale to 0 – 40 mmHg and given a clear colour scheme. Currently, it is difficult to see the data points.

12. Supplementary Figure S5 is far too small to read. Consider splitting and enlarging into several figure panels.

[1] Trotter, M.J. (1990). ‘Intermittent blood flow in the murine SCCVII squamous cell carcinoma’. PhD Thesis. University of British Columbia.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Computational Biology data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: No: code for reproducing simulations not made available (to the best of my knowledge)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No: No code repository provided.

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Attachment

Submitted filename: Kingsley_PCB_refMarch2021.pdf

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009206.r003

Decision Letter 1

Philip K Maini, Feilim Mac Gabhann

1 Jun 2021

Dear Dr. Rejniak,

Thank you very much for submitting your manuscript "Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations" for consideration at PLOS Computational Biology. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Philip K Maini

Associate Editor

PLOS Computational Biology

Feilim Mac Gabhann

Editor-in-Chief

PLOS Computational Biology

***********************

A link appears below if there are any accompanying review attachments. If you believe any reviews to be missing, please contact ploscompbiol@plos.org immediately:

[LINK]

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: I have read through the revised manuscript and the authors response to the comments I raised. Overall, the authors have done a good job of addressing most of the comments that were raised. However, there are a few places where further clarification is needed. I will list these below.

Comment 2. The authors justify their decision not to include dimensional estimates of the length scales involved in their model by stating that there is no spatial scale provided in the experimental paper on which there work is based. I do not consider this sufficient justification – the authors could, for example, estimate typical length scales either from the existing experimental literature or length scales consistent with the vascular densities that they use in their simulations. I would encourage them to do this, so that the reader more readily understands the physical situations that they are modelling.

Comment 3. The literature review in the discussion does not reflect the range of modelling approaches in the literature. The authors may find the following references of relevance:

• T Roque, L Risser, V Kersemans, S Smart, D Allen, P Kinchesh, S Gilchrist, AL Gomes, JA Schnabel, MA Chappell (2016). A DCE-MRI Driven 3-D Reaction-Diffusion Model of Solid Tumour Growth. IEEE Trans Medical Imaging (DOI:10.1109/TMI.2017.2779811)

• C Villa, MAJ Chaplain & T Lorenzi (2021). Modeling the emergence of phenotypic heterogeneity in vascularized tumors. SIAM J Applied Mathematics, 81(2), 434-453.

Comment 5: please can the authors clarify the relevance of measured changes in pyruvate levels obtained from in vitro experiments. I do not understand how changes in oxygen consumption in response to changes in pyruvate levels provide information about how cells response to changes in oxygen levels. Equally, I respectfully disagree that the impact of changes in oxygen levels on stromal cells has not been studied in the literature. See for example G Solani et al (2011), B Zhao et al (2016).

Comment 6: please clarify what an L2-norm of 10^{-10} means – the significance of this value will depend on the oxygen distributions being measured.

Comment 8: I do not understand why it takes longer for the system to reach a steady state as the density of cells increases. For a domain of the same size, the diffusive timescale will be the same. Does the dominant balance change in some way? The justification here could be further clarified

If the authors can satisfactorily address the above comments, then I would be very happy to recommend their article for publication. It is a great piece of work, improved with the revisions they have made.

Reviewer #2: In the revised manuscript, the authors have provided increased clarity and detail, particularly in the introduction and discussion, which has elevated the manuscript. I would also like to thank the authors on their detailed response particularly with regard morphological heterogeneities. Their comments have satisfied my initial concerns. I appreciate that more tumour-specific functional and architectural heterogeneities can by incorporated in future work, which has been noted in the discussion.

Subject to the minor comments below, I recommend this manuscript for publication and congratulate the authors.

- Lines 132 / 133 – the authors’ write “…too short for significant modifications in oxygen transport”. Is this comment regarding cellular update and interstitial transport?

- This reviewer apologises for their poor eyesight but Supporting Figure S4 is still too small. An alternative to reordering the figure panels may be to increase the resolution of the image in the Word Doc, as it is currently too pixelated even when zooming in.

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009206.r005

Decision Letter 2

Philip K Maini, Feilim Mac Gabhann

22 Jun 2021

Dear Dr. Rejniak,

We are pleased to inform you that your manuscript 'Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. 

Best regards,

Philip K Maini

Associate Editor

PLOS Computational Biology

Feilim Mac Gabhann

Editor-in-Chief

PLOS Computational Biology

***********************************************************

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009206.r006

Acceptance letter

Philip K Maini, Feilim Mac Gabhann

19 Jul 2021

PCOMPBIOL-D-21-00412R2

Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations

Dear Dr Rejniak,

I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Zita Barta

PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom ploscompbiol@plos.org | Phone +44 (0) 1223-442824 | ploscompbiol.org | @PLOSCompBiol

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text. This supporting information includes the computational procedure for resolving cell overlaps, discussion on the choice of model parameters, description of an algorithm for stabilizing oxygen gradient, and details of the optimization protocol used for fitting experimentally observed fluctuations.

    Fig A. Resolving cell overlapping conditions using repulsive forces. A left-top quarter of the tumor tissue domain characterized by 2% vascularity, 30% tumor cellularity, and 35% stromal cellularity with tumor cells represented by purple circles, stromal cells as pink circles, and vessels as red circles. A. An initial iteration 0 before repulsive forces are applied, showing overlapping cells and vessels. B. By iteration 25, repulsive forces have been applied and cell relocation has begun; only some cells remained overlapped. C. In iteration 100, all overlapping conditions have been resolved and cell positions have stabilized to reflect no overlapping. We allow vessels to overlap to represent irregular vessels shapes often seen in histology images.Fig B. Oxygen stabilization within the tumor tissue and the role of initial oxygen concentration. A-D. Snapshots showing oxygen distribution during the stabilization process, at iterations 0, 2000, 10000, and 18970. E. Temporal evolution of the average oxygen level from 0 mmHg until is stabilizes at the 29.89 mmHg with the stabilization error below 10−10. F. Tissue morphology with 3.5% vascular fraction, 55% tumor cellularity, and 30% stromal cellularity; vessels are represented by red circles, tumor cells by purple circles, and stromal cells by pink circles. G. Temporal evolution of average oxygen levels for 21 simulations of the same tissue shown in F. Each simulation is indicated by a different color that corresponds to initial uniform tissue oxygenation. All simulations stabilized around the 29.89 mmHg, however, simulations with lower initial oxygen concentrations have stabilized faster (cyan and blue lines) than those that started with higher initial oxygen concentrations (red and yellow lines). Table A. Initial tissue oxygenation vs. final stabilized oxygen level. Stabilized average oxygen levels for tissue of characteristics: 3.5% vascular fraction, 55% tumor cellularity, and 30% stromal cellularity, and initial uniform oxygen concentration reported as % of the maximal value of 60 mmHg. The stabilized oxygen levels units: mmHg. Fig C. Analysis of oxygen stabilization for tissues of identical characteristics but different morphologies. A. Levels of oxygen stabilization for 25 tissues of vascularity: 1.5%, tumor cellularity: 15%, stromal cellularity: 15%, with an average oxygenation level of 32.63 mmHg +/- 3.3 mmHg. B. Levels of oxygen stabilization for 25 tissues of vascularity: 2.5%, tumor cellularity: 30%, stromal cellularity: 35%, with an average oxygenation level of 29.98 mmHg +/- 2.4 mmHg. C. Levels of oxygen stabilization for 25 tissues of vascularity: 4%, tumor cellularity: 75%, stromal cellularity: 20%, with an average oxygenation level of 36.15 mmHg +/- 2.4 mmHg. D. Spatial gradient of oxygen with lowest average level among tissues in A. E-I. Spatial gradients of oxygen with highest (left) and lowest (right) average levels among tissues considered in A-C. Fig D. Convergence of the MABS method for influx and uptake schedules for ROI #1 (black). A. Experimental fluctuations (solid line) and simulated fluctuations (blue triangles) for the influx schedule with corresponding oxygen distributions at each time point (above the arrows). An inset shows tissue morphology. B. The convergence graphs for each of the 8 time segments with the converging influx rates (red pins) and the converging objective function values (blue pins). C. Experimental fluctuations (solid line) and simulated fluctuations (red stars) for the uptake schedule with corresponding oxygen distributions at each time point (above arrows). D. The convergence graphs for each of the 8 time segments with the converging uptake rates (red pins) and the converging objective function values (blue pins).

    (DOCX)

    Attachment

    Submitted filename: Kingsley_PCB_refMarch2021.pdf

    Attachment

    Submitted filename: Response_to_reviewers.pdf

    Attachment

    Submitted filename: Response to Reviewers2.docx

    Data Availability Statement

    The computational code is deposited at GitHub: https://github.com/rejniaklab/MultiCell-O2-fluctuations.


    Articles from PLoS Computational Biology are provided here courtesy of PLOS

    RESOURCES